| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1052361776 |
| P356 | DOI | 10.1186/1475-2840-11-60 |
| P932 | PMC publication ID | 3403890 |
| P698 | PubMed publication ID | 22672501 |
| P5875 | ResearchGate publication ID | 225277701 |
| P50 | author | Ilan Goldenberg | Q89825693 |
| P2093 | author name string | Alexander Tenenbaum | |
| Enrique Z Fisman | |||
| Jonathan Leor | |||
| Robert Klempfner | |||
| P2860 | cites work | Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 |
| Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins | Q33181373 | ||
| Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis | Q33695638 | ||
| Pleiotropic effects of statins. | Q34107414 | ||
| Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data | Q34128612 | ||
| Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective | Q35174193 | ||
| Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women | Q35501308 | ||
| Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme | Q35777074 | ||
| Factors contributing to increased platelet reactivity in people with diabetes | Q37139534 | ||
| Vildagliptin: a review of its use in type 2 diabetes mellitus | Q37801906 | ||
| Diabetes and antiplatelet therapy in acute coronary syndrome. | Q37846051 | ||
| Adiposopathy is "sick fat" a cardiovascular disease? | Q37890583 | ||
| Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure | Q38787227 | ||
| Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease | Q40596987 | ||
| Severe hypoglycemia and risks of vascular events and death | Q42868535 | ||
| Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis | Q42987834 | ||
| Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients | Q43013436 | ||
| Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. | Q46209636 | ||
| Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s). | Q46359419 | ||
| Protective role of adiponectin on endothelial dysfunction induced by AGEs: A clinical and experimental approach | Q59744870 | ||
| Pleiotropic effects of statins in atherosclerosis and diabetes | Q73909417 | ||
| Clinical guidelines for older adults with diabetes mellitus | Q79260474 | ||
| Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia | Q82587933 | ||
| Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse | Q83124022 | ||
| Using clinical guidelines designed for older adults with diabetes mellitus and complex health status | Q83202060 | ||
| FDA rejects novel diabetes drug over safety fears | Q83448627 | ||
| Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications | Q83649605 | ||
| Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study | Q83731087 | ||
| American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan | Q83808238 | ||
| Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients | Q84692016 | ||
| Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients | Q84820508 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| thrombosis | Q261327 | ||
| coronary artery disease | Q844935 | ||
| artery disease | Q18965518 | ||
| P304 | page(s) | 60 | |
| P577 | publication date | 2012-06-06 | |
| P1433 | published in | Cardiovascular Diabetology | Q2468083 |
| P1476 | title | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease | |
| P478 | volume | 11 |
| Q37568261 | Adiponectin and IL-6: Mediators of inflammation in progression of healthy to type 2 diabetes in Indian population |
| Q34109242 | Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. |
| Q38072259 | Cardiovascular effects of gliptins |
| Q34971736 | Cardiovascular safety profile of currently available diabetic drugs |
| Q43658383 | Change in levels of C-reactive protein (CRP) and serum cortisol in morbidly obese patients after laparoscopic sleeve gastrectomy |
| Q51322645 | Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. |
| Q26750414 | Hypoglycemic agents and potential anti-inflammatory activity |
| Q85643107 | Liquiritin attenuates advanced glycation end products-induced endothelial dysfunction via RAGE/NF-κB pathway in human umbilical vein endothelial cells |
| Q53355575 | Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. |
| Q33716972 | The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study |
Search more.